News
SYRS
--
0.00%
--
Roth Capital Maintains Buy on Syros Pharmaceuticals, Raises Price Target to $23
Roth Capital analyst Zegbeh Jallah maintains Syros Pharmaceuticals (NASDAQ:SYRS) with a Buy and raises the price target from $20 to $23.
Benzinga · 2d ago
Roth Capital Adjusts Price Target on Syros Pharmaceuticals to $23 From $20, Maintains Buy Rating
MT Newswires · 2d ago
Oppenheimer Adjusts Syros Pharmaceuticals PT to $9 From $13, Maintains Outperform Rating
MT Newswires · 4d ago
Syros Posts Updated Data From CDK7 Inhibitor In Various Solid Tumor Settings
Benzinga · 5d ago
BRIEF-Syros Presents New Data From Phase 1 Trial Of Sy-5609
reuters.com · 5d ago
Syros Pharma Highlights Presentation Of New Data From Phase 1 Trial Of SY-5609
Updated Dose-Escalation Data Demonstrate Clinical Activity in Heavily Pre-treated Patients Across Multiple Tumor Types Plan to Initiate Expansion Evaluating SY-5609 in Combination with Chemotherapy in Pancreatic Cancer
Benzinga · 5d ago
Syros Presents New Data from Phase 1 Trial of SY-5609 and Details Three-Pronged Combination Strategy to Advance SY-5609 in Solid Tumors and Blood Cancer
--Plan to Initiate Expansion Evaluating SY-5609 in Combination with Chemotherapy in Pancreatic Cancer in 4Q 2021
Business Wire · 5d ago
Syros Presents Phase 1 Data on SY-5609 Showing Clinical Activity Against Several Tumor Types
MT Newswires · 5d ago
Are Options Traders Betting on a Big Move in Syros (SYRS) Stock?
Investors need to pay close attention to Syros (SYRS) stock based on the movements in the options market lately.
Zacks · 5d ago
48 Biggest Movers From Friday
Gainers Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) shares jumped 135.4% to settle at $5.32 on Friday. The stock possibly traded higher following favorable data results by AstraZeneca for patients with unresectable, stage 3 non-small cell lung cancer.
Benzinga · 5d ago
SYRS, BGRY and OPAD among mid-day movers
Gainers: Helbiz (NASDAQ:HLBZ) +135%. Corvus Pharmaceuticals (NASDAQ:CRVS) +77%. Innate Pharma (NASDAQ:IPHA) +37%. Worksport (OTCQB:WKSP) +20%. Priority Technology Holdings (NASDAQ:PRTH) +15%. Entasis Therapeutics (NASDAQ:ETTX) +15%. Capital Senior Living C...
Seekingalpha · 09/17 16:21
25 Stocks Moving In Friday's Mid-Day Session
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 92.7% to $17.35 after the company announced its media unit has entered into an agreement with FOX Networks to broadcast the Italian Serie B championship across the USA and the Caribbean.
Benzinga · 09/17 16:05
Corvus Pharmaceuticals, Innate Pharma lead healthcare gainers; Protagonist Therapeutics, TCR2 Therapeutics among major losers
Gainers: Corvus Pharmaceuticals (NASDAQ:CRVS) +73%, Innate Pharma (NASDAQ:IPHA) +51%, SmileDirectClub (NASDAQ:SDC) +12%, Biomerica (NASDAQ:BMRA) +9%, I-Mab (NASDAQ:IMAB) +6%. Losers: Protagonist Therapeutics (NASDAQ:PTGX) -62%, TCR2 Therapeutics (NASDAQ:TC...
Seekingalpha · 09/17 15:00
BRIEF-Syros To Present New Data From Phase 1 Clinical Trial Of SY-5609 In Oral Presentation At ESMO Congress 2021
reuters.com · 09/13 11:31
Syros to Present New Data from Phase 1 Clinical Trial of SY-5609 in Oral Presentation at ESMO Congress 2021
CAMBRIDGE, Mass., September 13, 2021--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it will present new data from the dose-escalation portion of the Phase 1 clinical...
Business Wire · 09/13 11:00
BRIEF-Syros Announces Appointment Of Deborah Dunsire To Its Board Of Directors
reuters.com · 09/10 11:31
Syros Announces Appointment of Deborah Dunsire, M.D., to Its Board of Directors
CAMBRIDGE, Mass., September 10, 2021--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Deborah Dunsire, M.D., to the Company’s Board of Directors. Dr. Dun...
Business Wire · 09/10 11:30
Syros Pharmaceuticals Doses First Patient in Phase 2 Trial of Tamibarotene, Venetoclax, Azacitidine Combination to Treat AML
MT Newswires · 09/09 12:29
Syros Announces First Patient Dosed In SELECT-AML-1 Trial Of Tamibarotene In Combination With Venetoclax And Azacitidine In Newly Diagnosed Unfit AML
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the SELECT-AML-1 clinical trial of
Benzinga · 09/09 12:03
Syros Announces First Patient Dosed in SELECT-AML-1 Trial of Tamibarotene in Combination with Venetoclax and Azacitidine in Newly Diagnosed Unfit AML
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the first patient has been dosed in the SELECT-AML-1 clinical trial of tamibarotene, its first-in-class selective retin...
Business Wire · 09/09 12:00
Webull provides a variety of real-time SYRS stock news. You can receive the latest news about Syros Pharms through multiple platforms. This information may help you make smarter investment decisions.
About SYRS
Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on redefining the power of small molecules to control the expression of genes. It is focused on developing treatments for cancer and diseases resulting from mutations of a single gene (monogenic diseases) and building a pipeline of gene control medicines. Its product candidates include SY-1425, SY-5609 and SY-2101. SY-1425 is a selective retinoic acid receptor alpha (RAR), agonist that is being evaluated in combination with azacytidine, used to treat acute myeloid leukemia (AML). SY-5609 is a selective and potent oral inhibitor of cyclin-dependent kinase 7 (CDK7) that is being evaluated in the dose escalation portion in patients with select advanced solid tumors. SY-2101 is an oral form of arsenic trioxide (ATO) being developed for the treatment of AML.